The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. The company said that, additionally, a range of active compounds are protected, each related to the active ingredient in PH-10.
Craig Dees, CEO of Provectus, said: “Coming on the heels of our recent patent in India for PV-10, our lead oncology agent, this pending patent for PH-10 is yet another major milestone for us since it secures access to a market that represents roughly one-fifth of the world’s population. Moreover, since the Indian pharmaceutical industry is becoming an important player in the global marketplace, this patent will afford Provectus the right of ownership for products sold or made in India.”